

Journal of Neuroscience Methods 161 (2007) 185–198

www.elsevier.com/locate/jneumeth

Invited review

Neurobiology of animal models of attention-deficit hyperactivity disorder

Vivienne Ann Russell ∗

Department of Human Biology, Faculty of Health Sciences, University of Cape Town, Anzio Road, Observatory 7925, South Africa Received 17 September 2006; received in revised form 4 December 2006; accepted 14 December 2006

Abstract

Attention-deficit hyperactivity disorder (ADHD) is a heterogeneous, highly heritable, disorder resulting from complex gene–gene and gene–environment interactions. The defining symptoms of hyperactivity, impulsivity and impaired sustained attention are not unique to ADHD. It is therefore not surprising that animals with distinctly different neural defects model the behavioural characteristics of the disorder. Consistent with ADHD being a developmental disorder, animal models are either genetic (spontaneously hypertensive rats (SHR), dopamine transporter (DAT) knock-out mice, SNAP-25 mutant mice, mice expressing a mutant thyroid receptor) or have suffered an insult to the central nervous system during the early stages of development (anoxia, 6-hydroxydopamine). It appears that neural transmission is impaired by either direct disruption of dopaminergic transmission or a more general impairment of neurotransmission that gives rise to compensatory changes in monoaminergic systems that are not sufficient to completely normalize neural function. In general, results obtained with animal studies suggest that dopamine neurons are functionally impaired. However, evidence obtained from some animal models suggests that the noradrenergic and serotonergic neurotransmitter systems may be the target of drugs that ameliorate ADHD symptoms.

© 2007 Elsevier B.V. All rights reserved.

Keywords: Norepinephrine; Dopamine; Attention; Hyperactivity; SHR; Thyroid hormone

Contents

1. Attention-deficit/hyperactivity disorder

Development of the human brain follows a precise genetically determined programme that is subject to modification by the environment ([Toga et al., 2006\).](#page-13-0) During the first 3–4 years of life, stimulation and experience produce an initial increase

Tel·+27 21 4066243· fax: +27 21 4487226 *E-mail address:* [Vivienne.Russell@curie.uct.ac.za.](mailto:Vivienne.Russell@curie.uct.ac.za)

^{0165-0270/\$ –} see front matter © 2007 Elsevier B.V. All rights reserved. doi[:10.1016/j.jneumeth.2006.12.005](dx.doi.org/10.1016/j.jneumeth.2006.12.005)

in dendritic branching and synaptic contacts on neurons [\(Toga](#page-13-0) [et al., 2006\).](#page-13-0) This is followed by dendritic pruning and synapse elimination which occurs over several years into late adolescence to produce more efficient neural circuits that continue to be remodeled throughout life [\(Toga et al., 2006\).](#page-13-0) Any disruption of this process can result in impaired brain function. Attentiondeficit/hyperactivity disorder (ADHD) is a heterogeneous but nevertheless highly heritable disorder resulting from complex gene-gene and gene-environment interactions [\(Faraone, 2004;](#page-11-0) [Thapar et al., 2005\).](#page-11-0) Meta-analyses suggest that polymorphisms in the genes that encode the D4 and D5 subtypes of the dopamine receptor (DRD4 and DRD5), the dopamine transporter (DAT), SNAP-25 (a protein required for neurotransmitter release as well as transfer of glutamate NMDA receptor subunits to the plasma membrane), and the serotonin transporter, are associated with ADHD [\(Thapar et al., 2005\).](#page-13-0) Environmental risk factors include prenatal exposure to drugs such as alcohol and nicotine, obstetric complications, head injury, and psychosocial adversity [\(Biederman and Faraone, 2005; Romano et al., 2006\).](#page-10-0) ADHD is a behavioural disorder characterized by difficulty in sustaining attention, impulsivity and hyperactivity ([American Academy of](#page-10-0) [Pediatrics, 2000\).](#page-10-0) It affects 5–10% of children worldwide and persists through adolescence into adulthood in about half of the affected individuals ([Faraone et al., 2003\).](#page-11-0)

2. Animal models of ADHD

Diagnosis of ADHD depends on behavioural criteria and so animal models of the disorder should mimic the major symptoms of hyperactivity, impulsivity and impaired sustained attention. Very few animal models have been as extensively studied as the spontaneously hypertensive rat (SHR) and so much of this review will focus on SHR. However, each of the animal models of ADHD provides unique insight into possible gene defects and environmental conditions that might predispose an individual to ADHD, and so these will be considered as well. ADHD itself is a heterogeneous disorder, no two children with ADHD are identical, and so it is not surprising that many different animal models with distinctly different neural defects model the behavioural characteristics of the disorder.

In general, results obtained with animal studies suggest that monoaminergic systems, particularly the dopaminergic systems are functionally altered in ADHD (for review see [Russell et al.,](#page-13-0) [2005\).](#page-13-0) Consistent with ADHD being a developmental disorder, animal models are either genetic (e.g. DAT knock-out, SNAP-25 mutant mice) or have suffered an insult to the central nervous system during the early stages of development (e.g. anoxia, 6 hydroxydopamine), whereas exposure to toxins in adulthood does not produce the characteristic ADHD-like behaviour (for review see [Russell et al., 2005\).](#page-13-0) It appears that there are several different ways in which neural transmission is impaired in animal models of ADHD which involve either direct disruption of dopaminergic transmission or a more general impairment of neurotransmission, such as impaired calcium signaling in SHR or SNAP-25 in the coloboma mutant mouse, that gives rise to compensatory changes in monoaminergic systems that are not sufficient to meet demands. The details of these models have

been extensively reviewed by [Russell et al. \(2005\)](#page-13-0) but there have been interesting new data that provide novel insights that will be reviewed in this paper.

2.1. Transgenic mice expressing mutant thyroid hormone receptor

It has been known for some time that many children with elevated thyroid stimulating hormone (TSH) and resistance to thyroid hormone, display symptoms of ADHD ([Burd et al.,](#page-10-0) [2003\).](#page-10-0) Thyroid hormone directly controls the development of several brain systems associated with the regulation of attention, locomotor activity, motivation, and impulsive behaviour [\(Siesser et al., 2006\).](#page-13-0) Genes that encode proteins involved in myelination (suggested to be impaired in ADHD) ([Russell et](#page-13-0) [al., 2006\)](#page-13-0) and the development of neurotransmitter systems that regulate attention and motor activity (cholinergic, dopaminergic, and noradrenergic neurotransmitter systems) are all regulated by thyroid hormone ([Siesser et al., 2006\).](#page-13-0) Consistent with ADHD being a developmental disorder, rats made transiently hyperthyroid as pups (but not as adults) are hyperactive and exhibit elevated striatal dopamine turnover [\(Rastogi and Singhal, 1976;](#page-12-0) [Siesser et al., 2006\).](#page-12-0) Male transgenic mice expressing a human mutant thyroid receptor ($TR\beta1$, limited to the pituitary by the glycoprotein hormone α -subunit promoter) displayed all of the characteristic symptoms of ADHD: inattention seen as slow reaction times and inaccuracy in an operant task, hyperactivity that was not evident in a novel environment but developed gradually after repeated exposure to the environment, and impulsivity seen as an inability to inhibit a response during the extinction phase of an operant task (when reinforcer was no longer presented) as well as an inability to delay a response in order to obtain a larger reinforcer ([Siesser et al., 2006\).](#page-13-0)

Striatal dopamine turnover was increased in $TR\beta1$ transgenic mice and, similar to ADHD, their hyperactivity was reduced by methylphenidate [\(Siesser et al., 2006\).](#page-13-0) Elevated striatal dopamine turnover has been observed in other models of ADHD (DAT-knockout mouse) and is suggestive of DAT dysfunction [\(Jones et al., 1998; Siesser et al., 2006; Zhuang et al.,](#page-11-0) [2001\).](#page-11-0) As adults, the TR β 1 transgenics had normal thyroid hormone levels. However at 33 days of age when the thyroid system is most active, male $TR\beta1$ transgenic mice had significantly elevated TSH levels compared to wild-type controls ([Siesser](#page-13-0) [et al., 2006\).](#page-13-0) It appears that disruption of the normal development of neural circuits in the brain by impaired thyroid hormone feedback control of TSH secretion gives rise to disturbances in, amongst others, dopaminergic transmission as well as the behavioural symptoms that define ADHD. This is a novel finding which adds to the increasing number of potential models for ADHD and also shows how general and diverse the possible causes are that can give rise to the ADHD phenotype.

2.2. ADHD symptoms are not unique to ADHD: in utero exposure to alcohol

ADHD symptoms are not unique to ADHD but are found in other disorders such as phenylketonuria ([Realmuto et al., 1986;](#page-12-0) [Sullivan and Chang, 1999\)](#page-12-0) and fetal alcohol syndrome ([Nash et](#page-12-0) [al., 2006; Riikonen et al., 2005\).](#page-12-0) Phenylketonuria results from high concentrations of phenylalanine that arise from an inability to convert it into tyrosine, and which inhibit the transport of neutral amino acids such as tyrosine and tryptophan across the blood brain barrier, thereby limiting the synthesis of the three principle monoamine transmitters. Prenatal exposure to ethanol affects mainly dopaminergic transmission and causes hyperactivity ([Gibson et al., 2000\).](#page-11-0) Rats exposed to ethanol prenatally show attention deficits that are similar to those of children with fetal alcohol syndrome and ADHD ([Hausknecht et al., 2005\).](#page-11-0) Prenatal ethanol exposure produced a persistent reduction in the number of spontaneously active dopamine neurons in the ventral tegmental area of the midbrain (VTA). Acute *d*-amphetamine treatment normalized the activity of dopamine neurons after prenatal ethanol exposure, it increased the number of spontaneously active VTA neurons and reduced their firing rate ([Xu and Shen,](#page-13-0) [2001\).](#page-13-0) Similarly, repeated methylphenidate treatment normalized VTA dopamine neuron activity in rats exposed to ethanol prenatally whereas repeated methylphenidate treatment of control rats increased the excitability of VTA dopamine neurons causing a transient increase in activity followed by a decrease in spontaneous activity lasting more than 30 days ([Shen and](#page-13-0) [Choong, 2006\).](#page-13-0) These results suggest that dopamine transmission is impaired in rats exposed to ethanol prenatally, similar to animal models of ADHD.

2.3. In utero exposure to nicotine

Epidemiological evidence reveals that ADHD is associated with prenatal exposure to nicotine [\(Mick et al., 2002; Milberger](#page-12-0) [et al., 1998; Thapar et al., 2003\).](#page-12-0) Prenatal nicotine increased spontaneous locomotion in mice [\(Paz et al., 2006\).](#page-12-0) Deletion of the gene encoding the β 2-subunit of the nicotinic acetylcholine receptor caused mice to display the defining ADHD symptoms of inattention, lack of inhibitory control and hyperactivity ([Granon and Changeux, 2006\).](#page-11-0) Agonists of the α 4 β 2-nicotinic receptor reduced the ADHD-like behaviour in the mouse model ([Granon and Changeux, 2006\).](#page-11-0) Nicotinic agonists also reduced spontaneous alternation deficits in young stroke-prone SHR, an effect that was prevented by an α 4 β 2-nicotinic receptor antagonist suggesting that α 4 β 2-nicotinic agonists may be useful for the treatment of attentional deficits in ADHD ([Ueno et al.,](#page-13-0) [2002a\).](#page-13-0)

2.4. Anoxia in neonatal rat

Anoxia increases the risk of ADHD [\(Lou, 1996\).](#page-12-0) Neonatal anoxia caused a sequence of acute and persistent neurochemical changes in rat monoaminergic systems as well as transient hyperactivity and spatial memory impairment that persisted into adulthood ([Dell'Anna, 1999; Dell'Anna et al., 1993; Iuvone et](#page-11-0) [al., 1996\).](#page-11-0) Acute anoxia caused a transient decrease followed by an increase after 1 week in cerebellar norepinephrine levels [\(Dell'Anna et al., 1993\).](#page-11-0) Dopamine and serotonin levels decreased and then metabolite levels increased post ischaemia ([Dell'Anna et al., 1993\).](#page-11-0) The increase in serotonin and dopamine metabolites persisted into adulthood, suggesting that dopamine turnover is increased. Tyrosine hydroxylase mRNA levels were increased in VTA and substantia nigra of perinatally asphyxiated rats suggesting increased dopamine synthesis consistent with increased turnover. Dopamine D1 receptor (DRD1) and D2 receptor (DRD2) mRNA levels were increased in the striatum suggesting altered release of dopamine [\(Gross et al., 2000\).](#page-11-0) These findings demonstrate the complex temporal sequence of compensatory changes that occur in monoaminergic systems following perinatal insult to the nervous system and implicate all three monoaminergic systems in spatial memory impairment.

2.5. Coloboma mutant mouse

The SNAP-25 deficient mutant coloboma mouse provides an interesting model of ADHD, especially since SNAP-25 polymorphisms have been associated with the disorder [\(Barr et](#page-10-0) [al., 2000; Mill et al., 2002\).](#page-10-0) SNAP-25 regulates membrane trafficking. It is required presynaptically for the release of neurotransmitters as well as postsynaptically where it is involved in the translocation of proteins (e.g. NMDA receptor subunits) to the cell membrane. Altered expression of SNAP-25 is therefore likely to impair neuronal function. Coloboma mice displayed impulsivity and impaired inhibition in a delayed reinforcement task [\(Bruno et al., 2006\)](#page-10-0) as well as spontaneous hyperactivity that was reduced by *d*-amphetamine but not methylphenidate ([Hess et al., 1996; Wilson, 2000\).](#page-11-0) The difference in effect is likely to be due to the different actions of these two drugs. Both increase the extracellular concentration of catecholamines through blockade of the dopamine and norepinephrine transporters, but *d*-amphetamine also increases the release of these neurotransmitters.

Glutamate release from cortical synaptosomes is reduced in the coloboma mouse ([Raber et al., 1997\).](#page-12-0) Depolarization-evoked release of dopamine from dorsal striatal slices is also decreased and dopamine metabolite concentrations are decreased in the ventral striatum ([Jones et al., 2001a; Raber et al., 1997\)](#page-11-0) suggesting that the coloboma mouse has a hypofunctional dopaminergic system, similar to SHR ([Russell et al., 2005\).](#page-13-0) DRD2 expression is increased in the VTA and substantia nigra, consistent with increased inhibition of dopamine neuron activity ([Jones et al.,](#page-11-0) [2001b\).](#page-11-0) Tyrosine hydroxylase expression is unaltered in VTA and substantia nigra of the coloboma mouse ([Jones et al., 2001b\).](#page-11-0) Noradrenergic function appears to be increased in coloboma mice. Tyrosine hydroxylase and α_{2A} -adrenoceptor expression is increased in the locus coeruleus and norepinephrine concentrations are increased in striatum of coloboma mice ([Jones](#page-11-0) [et al., 2001b\).](#page-11-0) Experimental depletion of norepinephrine with *N*-(2-chloroethyl)-*N*-ethyl-2-bromobenzylamine hydrochloride (DSP-4) reduced hyperactivity, restored latent inhibition but did not ameliorate impulsivity of the coloboma mice ([Bruno](#page-10-0) [et al., 2006; Jones and Hess, 2003\).](#page-10-0) α_{2C} - (but not α_{2A} - or α_{2B} -)Adrenergic receptor antagonists also reduced the hyperactivity of coloboma mice [\(Bruno and Hess, 2006\).](#page-10-0) The β -adrenergic receptor antagonist propranolol and the α_1 -adrenergic receptor antagonist prazosin had little effect. This suggested that motor activity in coloboma mice is caused by a hyperactive noradrenergic system but the hyperactivity is not completely abolished by depletion of norepinephrine, suggesting that additional factors contribute to the mutant phenotype ([Jones and Hess, 2003\).](#page-11-0) An imbalance between noradrenergic hyperfunction and dopamine hypofunction may be a determining factor, as suggested for SHR [\(Russell et al., 2005\).](#page-13-0)

2.6. 6-OHDA-lesioned rat

Neonatal 6-OHDA-lesioned rats have also been suggested to be a useful model for ADHD. They display hyperactivity and impaired learning in a spatial discrimination task which improves after methylphenidate or *d*-amphetamine treatment but they are not impulsive [\(Davids et al., 2002, 2003; Luthman et](#page-11-0) [al., 1989; Shaywitz et al., 1978\).](#page-11-0) Rat pups lesioned on postnatal day 1 displayed hyperactivity in adulthood ([Luthman et al.,](#page-12-0) [1989\).](#page-12-0) They showed an initial decrease in spontaneous motor behaviour when placed in a novel environment but after repeated testing their activity was increased relative to controls ([Luthman](#page-12-0) [et al., 1989\).](#page-12-0) Hyperactivity was accompanied by decreased dopamine in straitum, prefrontal cortex, septum, midbrain and amygdala ([Luthman et al., 1989\).](#page-12-0) Serotonin and serotonin transporter binding was increased in striatum but not cerebral cortex [\(Luthman et al., 1989; Zhang et al., 2002b\).](#page-12-0) Hyperactivity was not altered by DAT inhibitors but was greatly reduced by DRD4 antagonists as well as inhibitors of norepinephrine and serotonin transporters [\(Davids et al., 2002, 2003; Zhang](#page-11-0) [et al., 2001, 2002a\).](#page-11-0) These findings suggest that psychostimulants reduce hyperactivity of 6-OHDA lesioned rats by inhibiting norepinephrine and serotonin transporters. In addition to reducing norepinephrine uptake, inhibition of the norepinephrine transporter would reduce dopamine uptake into noradrenergic terminals in several brain areas including prefrontal cortex and nucleus accumbens and thereby exert effects on both dopaminergic and noradrenergic function in the brain.

2.7. DAT-knock-out mouse

DAT-knock-out (DAT-KO) mice have been suggested to model ADHD because they are hyperactive ([Gainetdinov and](#page-11-0) [Caron, 2000, 2001; Trinh et al., 2003\),](#page-11-0) demonstrate impaired extinction of responses in operant food reinforcement tasks [\(Hironaka et al., 2004\)](#page-11-0) and impaired learning and memory [\(Gainetdinov and Caron, 2001; Trinh et al., 2003\).](#page-11-0) Impulsivity has not been systematically investigated in DAT-KO mice. The absence of DAT in the DAT-KO mouse provides an extreme model of reduced midbrain DAT binding in adolescents with ADHD ([Jucaite et al., 2005\)](#page-11-0) and contrasts with several studies that found increased DAT in the striatum of children and adults with ADHD ([Cheon et al., 2003; Dougherty et al., 1999; Krause](#page-10-0) [et al., 2000\).](#page-10-0) The DAT-KO mouse nevertheless provides useful information concerning the neurobiological consequences of impaired DAT function.

In DAT-KO mice, dopamine is cleared very slowly from the synaptic cleft causing a 5-fold elevation of extracellular dopamine in the striatum, a hyperdopaminergic state [\(Gainetdinov et al., 1999\).](#page-11-0) However, electrically stimulated release of dopamine is decreased, suggesting that phasic release of dopamine is reduced and the dopamine system is hypofunctional [\(Gainetdinov et al., 1999\)](#page-11-0) similar to SHR and the coloboma mouse [\(Russell et al., 2005\).](#page-13-0) Unlike SHR, striatal DRD2 autoreceptors are nonfunctional and postsynaptic DRD1 and DRD2 are downregulated by approximately 50% in the striatum of DAT-KO mice ([Gainetdinov et al., 1999\).](#page-11-0) Hyperactivity in the DAT-KO mouse might be the result of increased dopamine tone or decreased phasic dopamine release with consequently impaired activation of postsynaptic DRD1 required for LTP (and LTD) to produce changes in synaptic strength necessary for associative learning and reinforcement of appropriate behaviour.

Inhibitors of the serotonin transporter as well as drugs that activate the serotonergic system dramatically reduced the hyperactivity of DAT-KO mice whereas specific inhibitors of the norepinephrine transporter or DAT were ineffective [\(Gainetdinov and Caron, 2001\).](#page-11-0) Results obtained with DAT-KO mice suggest that hyperactivity induced by high extracellular levels of dopamine can be reduced by enhancing serotonergic tone [\(Gainetdinov and Caron, 2001\).](#page-11-0) Antagonists of the $5-HT_{2A}$ receptor reversed the behavioural deficits of DAT-KO mice [\(Barr](#page-10-0) [et al., 2004\).](#page-10-0) Polymorphisms of the $5-HT_{2A}$ receptor gene have been associated with ADHD ([Levitan et al., 2002; Quist et al.,](#page-12-0) [2000\)](#page-12-0) suggesting that specific antagonists of the $5-HT_{2A}$ receptor may be useful in the treatment of ADHD. However, the relevance of this finding to ADHD is questionable since serotonin reuptake inhibitors are not effective in treating ADHD and serotonin uptake inhibitors increase motor activity [\(Biederman](#page-10-0) [et al., 2004; Gainetdinov and Caron, 2001\).](#page-10-0)

The DAT-KO mouse has been criticized as a model for ADHD because DAT-knockdown mice (expressing 10% of wild-type DAT) displayed excessive sequential stereotypy reflected as a complex serial pattern of grooming actions becoming more sequentially rigid and persistent [\(Berridge et al., 2005; Russell et](#page-10-0) [al., 2005\).](#page-10-0) This type of behaviour is not characteristic of ADHD but may serve as a model for Tourette's syndrome and obsessive compulsive disorder ([Berridge et al., 2005\).](#page-10-0) DAT-knockdown mice tended to be hyperactive, to walk in perseverative straight paths, and to over-pursue certain incentive stimuli, consistent with obsessive compulsive disorder ([Berridge et al., 2005\).](#page-10-0)

2.8. Selection of poor performers in the 5-CSRT test

Rats that are selected for poor performance in a 5-choice serial reaction time (5-CSRT) test provide a useful model of the inattentive subtype of ADHD in that they are selected for deficient sustained attention, they show poor choice accuracy towards the end of testing sessions, they demonstrate impulsiveness (premature responding) and they are not hyperactive [\(Barbelivien et al., 2001; Puumala et al., 1996\).](#page-10-0) Han:Wistar rats were food-deprived for 16 h before being trained to nosepoke an illuminated hole in order to obtain a food pellet. A nose-poke into an unlit hole or a failure to respond during the visual stimulus resulted in a punishment period of darkness [\(Puumala et al., 1996\).](#page-12-0) Poor performers were defined as those rats that achieved less than 64% correct responses [\(Puumala](#page-12-0)

[et al., 1996\).](#page-12-0) Responses recorded during the intertrial interval were considered premature and provided a measure of impulsivity. Methylphenidate treatment improved accuracy and reduced impulsiveness (at low doses) in poor performers ([Puumala et](#page-12-0) [al., 1996\).](#page-12-0) Activation of $5-HT_{2A}$ receptors increased the number of premature responses in normal animals [\(Koskinen et al.,](#page-11-0) [2000\)](#page-11-0) which suggests that $5-HT_{2A}$ receptor antagonists may be useful in treating symptoms of ADHD and is consistent with 5-HT2A receptor antagonists reducing ADHD-like behaviour in DAT-KO mice ([Barr et al., 2004\).](#page-10-0)

Evidence supports a role for dopamine in regulating the level of performance in the 5-CSRT task. In normal animals, *d*-amphetamine stimulated release of dopamine in the nucleus accumbens and caused a dose-dependent increase in premature responding [\(Robbins, 2002\).](#page-12-0) Microinfusion of a DRD1 agonist into the medial prefrontal cortex selectively impaired the accuracy of attentional performance in high performers in the 5-CSRT task [\(Granon et al., 2000\).](#page-11-0) In contrast, microinfusion of the DRD1 agonist into the medial prefrontal cortex of poor performers enhanced the accuracy of attentional performance; a low dose increased the speed at which correct responses were made [\(Granon et al., 2000\).](#page-11-0) These results suggest that dopamine function is reduced in poor performers of the 5-CRST task and that $5-\text{HT}_{2A}$ antagonists may be beneficial in the treatment of ADHD. This finding once again emphasizes the need to study animal models of ADHD rather than normal animals in order to gain insight into the mechanisms that underlie the beneficial effects of drugs used to treat children with ADHD.

2.9. SHR

The SHR exhibits all of the behavioural characteristics of ADHD when compared to its normotensive Wistar–Kyoto (WKY) control rat. Inattention is seen as increased percentage of errors in operant tasks, hyperactivity that is not present in novel, non-threatening situations, develops over time when reinforcers are infrequent [\(Sagvolden, 2000; Sagvolden et al.,](#page-13-0) [2005a,b; Wiersema et al., 2005\).](#page-13-0) Impulsivity also develops over time and is seen as an inability to inhibit a response during the extinction phase of an operant task as well as an inability to delay a response in order to obtain a larger reward [\(Bull et al.,](#page-10-0) [2000; Sagvolden, 2000; van den Bergh et al., 2006\).](#page-10-0) However, both SHR and WKY have been criticized ([Bull et al., 2000;](#page-10-0) [van den Bergh et al., 2006\).](#page-10-0) The WKY rat does not perform as well as other rat strains in certain behavioural tasks and is often less active than other rat strains ([Bull et al., 2000; van den](#page-10-0) [Bergh et al., 2006\).](#page-10-0) The results of behavioural studies are unfortunately inconsistent and depend on the demands of the task. [Sagvolden et al. \(2005a,b\)](#page-13-0) showed that SHR learn as quickly as WKY in an operant task that required the rat to learn to press a lever in order to obtain a reinforcer only when the reinforcer was presented within a few seconds after a correct behavioural response. However, SHR failed to learn a new rule when correct responses were reinforced intermittently after a delay of approximately 3 min. Furthermore, their accuracy of performance did not improve even after 25 trials ([Sagvolden et al., 2005a,b\).](#page-13-0) Similar results were obtained by Hand and coworkers [\(Hand et al.,](#page-11-0)

[2006\)](#page-11-0) who showed that SHR took longer than WKY to learn a novel response when reinforcement was delayed but not when reinforcer delivery was immediate.

Different levels of arousal can be confounding factors in behavioural testing ([Calzavara et al., 2004\).](#page-10-0) Young SHR performed poorly in a plus-maze discriminative avoidance task compared to WKY but after treatment with chlordiazepoxide, their anxiety levels were reduced and their performance improved ([Calzavara et al., 2004\).](#page-10-0) SHR performed poorly in tests of spatial memory, they made more errors than WKY, Wistar and Sprague–Dawley, they also failed to show improvement in a win-shift version of the water radial arm maze compared to WKY and Sprague–Dawley controls ([Clements and](#page-10-0) [Wainwright, 2006; Hernandez et al., 2003; Nakamura-Palacios](#page-10-0) [et al., 1996; Prediger et al., 2005; Wyss et al., 1992\).](#page-10-0) However, SHR sometimes performed as well or even better than controls ([Ferguson and Cada, 2004\).](#page-11-0) Inconsistencies could be due to different levels of arousal and anxiety. Increased norepinephrine release in prefrontal regions is associated with arousal and can influence performance of cognitive tasks ([Arnsten, 1998\).](#page-10-0) SHR have profound alterations in the noradrenergic neurotransmitter system ([Russell, 2001; Russell and Wiggins, 2000; Russell](#page-12-0) [et al., 2000a,b\).](#page-12-0) Autoreceptor-mediated feedback inhibition of norepinephrine release is impaired in prefrontal cortex and there appears to be increased release of norepinephrine in response to glutamate stimulation of AMPA receptors in prefrontal cortex and hippocampus of SHR [\(Russell, 2001; Russell and Wiggins,](#page-12-0) [2000; Russell et al., 2000a,b; H](#page-12-0)owells and Russell, unpublished). This could be altered by the level of arousal.

The physical requirements of the task can also produce variable results. For example, WKY took longer than SHR and Sprague–Dawley rats to acquire a task that required high response rates but equal to or better than the other strains when low rates of responding were required [\(Bull et al., 2000; van](#page-10-0) [den Bergh et al., 2006\).](#page-10-0) SHR displayed decreased acoustic startle response and decreased prepulse inhibition when compared to WKY, Lewis and Sprague–Dawley rats ([Ferguson and Cada,](#page-11-0) [2004; Vendruscolo et al., 2006\).](#page-11-0) The decreased startle response was a consistent finding across several studies but prepulse inhibition of acoustic startle was not, SHR performed as well as WKY and better than Sprague–Dawley rats in one study ([Van den Buuse, 2004\).](#page-13-0) SHR and WKY performed as well as Sprague–Dawley rats in a 5-CSRT task ([van den Bergh et al.,](#page-13-0) [2006\)](#page-13-0) which argues against the suggestion that poor performers of the 5-CSRT task may serve as a potential rodent model for the inattentive subtype of ADHD [\(Barbelivien et al., 2001; Puumala](#page-10-0) [et al., 1996; Russell et al., 2005\).](#page-10-0) SHR were also criticized for lack of response to methylphenidate in several behavioural tests ([van den Bergh et al., 2006\).](#page-13-0) It is possible that some of the tests were not targeting SHR's impairment specifically. It may also be unrealistic to expect identical effects of the drug on rodent and human behaviour if one considers the complexity of human behaviour and the relatively poorly developed prefrontal cortex in rodents. Despite this criticism, a lot of useful information has been gained by comparing differences between SHR and WKY behaviour in operant tasks and their neurochemistry. The strength of findings with animal models is seen when they are consistent across different laboratories and across different models of ADHD. Studies on SHR were the first to identify the importance of decreased stimulus-evoked release of dopamine which was subsequently found in the majority of animal models of ADHD [\(Russell et al., 2005\).](#page-13-0) This finding provides a firm basis for deficient dopamine-mediated strengthening of neural circuits which could give rise to deficient learning and impaired reinforcement of appropriate behaviour.

SHR is a genetic model of ADHD bred from progenitor Wistar–Kyoto rats ([Okamoto and Aoki, 1963\).](#page-12-0) A 160 bp insertion was found in the non-coding region upstream of exon 3 of the DAT gene of SHR ([Mill et al., 2005\)](#page-12-0) which is of significance since variable number tandem repeats in the 3 -untranslated region of the DAT gene has been associated with ADHD in several family studies [\(Bobb et al., 2005; Cook et al., 1995;](#page-10-0) [Dougherty et al., 1999; Kirley et al., 2003; Krause et al., 2000\).](#page-10-0) A possible disturbance in the regulation of transcription of the DAT gene is in agreement with findings that DAT gene expression is transiently reduced in SHR midbrain during the first postnatal month and increased in adult SHR compared to controls [\(Leo et al., 2003; Watanabe et al., 1997\).](#page-12-0) Alterations in DAT gene expression can affect dopamine uptake and reutilization. Decreased expression of DAT will reduce reuptake and increase metabolism of dopamine. Differences in dopamine metabolism have been reported for children and adults with ADHD ([Ernst et](#page-11-0) [al., 1998, 1999\)](#page-11-0) which is consistent with developmental changes in DAT expression and consequent changes in dopamine uptake. DOPA decarboxylase activity was found to be increased in the midbrain of children and decreased in prefrontal cortex of adults with ADHD compared to controls [\(Ernst et al., 1998, 1999\).](#page-11-0) Reduced DAT expression at a young age would reduce dopamine reuptake, thereby reducing dopamine reutilization and necessitating increased synthesis of dopamine by DOPA decarboxylase. In adults, increased expression of DAT might be expected to increase reuptake of dopamine, thereby reducing the need for synthesis by DOPA decarboxylase ([Russell et al., 2005\).](#page-13-0)

In addition to the hypothesis that dopaminergic systems are hypofunctional in ADHD, noradrenergic neurons have been suggested to be poorly regulated and hyperfunctional in the prefrontal cortex of children with ADHD [\(Arnsten, 1998; Russell,](#page-10-0) [2002; Solanto, 1998\).](#page-10-0) Normally, noradrenergic neurons enhance the signal-to-noise ratio in prefrontal and parietal cortices, amplify responses to attended stimuli, and reduce responses to irrelevant stimuli [\(Aston-Jones et al., 1994; Himelstein et al.,](#page-10-0) [2000\).](#page-10-0) These functions are defective in ADHD ([Himelstein et](#page-11-0) [al., 2000\).](#page-11-0)

The locus coeruleus noradrenergic neurons innervate the entire cerebral cortex, various subcortical areas, cerebellum and spinal cord. They play an important role in attention, arousal, orienting, and vigilance ([Solanto, 1998\).](#page-13-0) Locus coeruleus neurons respond selectively to attended (target) stimuli, tonic locus coeruleus activity corresponds to arousal state, and both very low and very high locus coeruleus activity are associated with impaired vigilance [\(Arnsten, 1998; Aston-Jones et al., 1994\).](#page-10-0) Noradrenergic neurons that project from the locus coeruleus to the prefrontal cortex release norepinephrine which guides behaviour by modulating the transfer of information through neuronal circuits that are responsible for selective and sustained attention ([Solanto, 1998\).](#page-13-0) Methylphenidate increases norepinephrine release and suppresses long-latency sensory responses in the primary somatosensory cortex of freely behaving rats ([Drouin et al., 2006\).](#page-11-0) Methylphenidate may improve sensory attention by increasing norepinephrine release in somatosensory cortex and suppressing "noise" [\(Drouin et al.,](#page-11-0) [2006\).](#page-11-0) Methylphenidate was suggested to have both direct effects in the somatosensory cortex as well as indirect effects through top–down (prefrontal cortex) influences on primary somatosensory cortex responsivity [\(Arnsten, 2006\).](#page-10-0)

Disturbances in norepinephrine metabolism in SHR are suggested by the finding that tyrosine hydroxylase gene expression is higher in the ventrolateral medulla oblongata of SHR than WKY [\(Reja et al., 2002a\),](#page-12-0) consistent with elevated norepinephrine concentration in several brain areas of SHR including locus coeruleus, substantia nigra and prefrontal cortex [\(de](#page-11-0) [Villiers et al., 1995\).](#page-11-0) Increased norepinephrine concentrations in SHR brain is consistent with downregulation of β -adrenoceptors in cerebral cortex of SHR ([Myers et al., 1981\).](#page-12-0)

Evidence suggests that there is an imbalance between dopaminergic and noradrenergic neurotransmission in the prefrontal cortex of SHR [\(Russell, 2002\).](#page-12-0) While dopamine release is decreased in SHR prefrontal cortex, norepinephrine concentrations are elevated. The noradrenergic system appears to be hyperactive as a result of impaired α_2 -autoreceptor regulation [\(Russell, 2002\).](#page-12-0)

Stimulus-evoked (electrically stimulated or K^+ -evoked) release of norepinephrine from prefrontal cortex slices of SHR was no different from that of WKY ([Russell et al., 2000a,b\).](#page-13-0) However, α_{2A} -adrenoceptor mRNA levels were decreased in SHR compared to WKY and α_2 -autoreceptor-mediated inhibition of norepinephrine release was less efficient in SHR than in WKY suggesting that α_2 -adrenoceptor function is impaired [\(Reja et al., 2002b; Russell et al., 2000a,b; Tsuda et al., 1990\).](#page-12-0) α_{2A} -Adrenoceptors are the subtype specifically expressed in the prefrontal cortex, so impaired α_{2A} -adrenoceptor function would be expected to impair cognition [\(Arnsten, 1998; Franowicz et](#page-10-0) [al., 2002\).](#page-10-0)

Decreased α_2 -autoreceptor-mediated regulation of norepinephrine neurons and impaired inhibition of norepinephrine release may be particularly disruptive to the function of target structures when the firing rate of locus coeruleus neurons is high, causing excessive spillover of norepinephrine into the extracellular space. Repeatedly increased release of norepinephrine from sympathetic nerve terminals could give rise to stressdependent development of hypertension in SHR [\(Printz et al.,](#page-12-0) [2003\).](#page-12-0) Expression of the gene encoding $G_{i\alpha}$ (the G-protein subunit that inhibits cAMP formation from ATP by adenylyl cyclise) is increased in SHR aorta at 2 weeks of age, possibly reflecting an attempt by a target organ to decrease the effect of increased norepinephrine release from sympathetic nerve endings. Poorly controlled norepinephrine release could also give rise to excessive activation of α_1 -adrenoceptors in the prefrontal cortex, impairing its function. Other noradrenergic terminal areas in the central nervous system may be similarly affected. These findings suggest that the noradrenergic system is hyperactive in SHR, particularly in response to stress, and supports the hypothesis that there is an imbalance between norepinephrine hyperfunction and dopamine hypofunction in ADHD.

The underlying defect in SHR appears to be a disturbance in calcium metabolism not only in brain but also in other tissues including vascular smooth muscle [\(Fellner and Arendshorst,](#page-11-0) [2002; Horn et al., 1995; Lehohla et al., 2001; Ohno et al., 1996,](#page-11-0) [1997; Oshima et al., 1991; Tabet et al., 2004\).](#page-11-0) Increased intracellular calcium concentrations have been attributed to genetic abnormalities in $Ca^{2+}ATP$ ase [\(Horn et al., 1995; Ohno et al.,](#page-11-0) [1996, 2005\).](#page-11-0)

Increased intracellular calcium levels can have several consequences (i) reduced calcium influx into neurons in response to depolarization, due to a decreased calcium gradient across the cell membrane, would decrease neurotransmitter release (ii) impaired calcium signaling [e.g. decreased NMDA-stimulated calcium influx into postsynaptic cells, [Lehohla et al., 2001\]](#page-12-0) with subsequent derangement of calcium-dependent protein kinase and phosphatase activity [e.g. protein kinase C activity is increased in SHR, [Tsuda et al., 2003\],](#page-13-0) and (iii) impaired mitochondrial function, giving rise to increased levels of reactive oxygen species, such as the superoxide anion and hydrogen peroxide [\(Chan et al., 2006\)](#page-10-0) and impaired ATP synthesis ([Doroshchuk et al., 2004\).](#page-11-0) One possible consequence of the elevated intracellular calcium concentration is that calciumdependent potassium channels are constitutively open in SHR, causing the cell membrane to be hyperpolarized and therefore refractory to α_2 -adrenoceptor-mediated inhibition [\(Fauaz et al.,](#page-11-0) [2003\).](#page-11-0) A neuron will only fire if the cell membrane is sufficiently depolarized to reach threshold for generation of an action potential at the axon hillock. If the membrane is hyperpolarized it will require greater excitatory input to reach the threshold for firing. Similarly, hyperpolarization of the axon terminal will cause less neurotransmitter to be released because the membrane potential will be more negative and hence the duration of opening of voltage-gated calcium channels will be reduced. If the membrane is hyperpolarized then α_2 -adrenoceptor activation is less likely to have an effect on the membrane (because its inhibitory action depends on hyperpolarization of the membrane) which could explain impaired α_2 -autoreceptor-mediated feedback inhibition of norepinephrine release observed in prefrontal cortex and brain stem of SHR ([Russell et al., 2000a,b;](#page-13-0) [Tsuda et al., 1990\).](#page-13-0)

Attempts to compensate for impaired calcium signaling due to reduced endoplasmic reticulum $Ca^{2+}ATP$ ase function, include enhanced calcium entry through L-type calcium channels and store-operated channels in vascular smooth muscle cells in SHR [\(Fellner and Arendshorst, 2002; Tabet et al., 2004\).](#page-11-0) Impaired vascular smooth muscle contraction could influence blood flow and impair brain function at times of high energy demand. A summary of the most important findings with SHR is presented in [Table 1.](#page-7-0)

Recently, the ADHD symptom of increased intra-individual variability during performance of high energy demanding cognitive tasks, was attributed to insufficient energy (lactate) supply by astrocytes to neurons at times of rapid and/or continuous firing [\(Russell et al., 2006\).](#page-13-0) This ubiquitous finding is not unique to ADHD but occurs in several disorders and may be attributed to inefficient information processing. Energy supply is a limiting factor in brain function ([Attwell and Gibb,](#page-10-0) [2005\).](#page-10-0) Inefficient neural transmission due to impaired learning in ADHD would place abnormally high demands on local energy resources and lead to intra-individual variability in responses to externally paced cognitive tasks. This aspect has not been tested in animal models of ADHD, however, consistent with impaired energy production, the synthesis rate of ATP is much lower in mitochondria of SHR brains than WKY ([Doroshchuk](#page-11-0) [et al., 2004\).](#page-11-0) Impaired mitochondrial function was attributed to calcium overload, as a result of $Ca^{2+}ATP$ ase not being able to pump Ca^{2+} efficiently into the endoplasmic reticulum and across the cell membrane into the extracellular space. Deficient endoplasmic reticular stores of Ca^{2+} would also impair the function of neurotransmitters acting on receptors that stimulate inositol triphosphate (IP_3) formation and release of calcium from intracellular stores [e.g. α_1 -adrenoceptors and metabotropic glutamate receptors that regulate astrocyte function, [Biber et al.,](#page-10-0) [1999; Glowinski et al., 1994\].](#page-10-0) Astrocytes provide lactate as a source of energy to rapidly and/or continuously firing neurons. Increased intra-individual variability in performance of tasks that require continual responses to rapid, externally-paced stimuli observed in subjects with ADHD as well as SHR has been attributed to inability of astrocytes to provide sufficient lactate at times of high energy demand [\(Russell et al., 2006\).](#page-13-0)

2.10. Non-human primates

Consistent with the hypothesis that ADHD symptoms result from impaired dopamine transmission, monkeys exposed to low doses of the dopamine neurotoxin 1-methyl-4-phenyl-1,2,3,6 tetrahydropyridine (MPTP) developed attentional deficits in the absence of gross motor dysfunction ([Roeltgen and Schneider,](#page-12-0) [1991, 1994\).](#page-12-0) The caudate-frontal cortex dysfunction was suggested to be consistent with the cognitive difficulties that exist in children with the inattentive subtype of ADHD and with the distribution of decreased cerebral blood flow found in children with ADHD. Monkeys given chronic low-dose MPTP displayed abnormalities in dopamine and norepinephrine metabolism ([Roeltgen and Schneider, 1991\).](#page-12-0) Monkeys developed deficits in maintenance of a response set, as well problems in shifting attentional sets, inattentiveness, impaired ability to sustain spatial attention or to focus attention, a deficit in motor readiness and planning, and impaired time estimation [\(Decamp and](#page-11-0) [Schneider, 2004\).](#page-11-0) An attentional cue presented prior to the stimulus significantly improved performance of a modified variable delayed response task, suggesting that procedures that enhance attention may be useful in ameliorating some of the "memory" deficits associated with diminished dopamine function ([Decamp et al., 2004\).](#page-11-0) Monkeys classified as poor learners in delayed response tasks which improve after treatment with methylphenidate ([Schneider et al., 1994\)](#page-13-0) had similar deficits in task persistence (i.e. errors of omission) as did MPTP-exposed monkeys, supporting the dopamine hypofunction hypothesis and suggesting that non-human primates selected for poor performance in attentional tasks may serve as a useful model for

Table 1 (*Continued*)

ADHD ([Roeltgen and Schneider, 1994\).](#page-12-0) Perhaps non-human primates could be selected using a multi-choice serial reaction time task similar to the 5-CSRT test used to identify rats that perform poorly in cognitive tasks, so that comparisons can be made across the different models of ADHD.

Experiments with non-human primates have shown that the prefrontal cortex is essential for keeping information in mind (i.e. sustaining attention over a delay), inhibiting distraction and dividing attention, while the parietal cortex is essential for perception and the allocation of attentional resources ([Arnsten,](#page-10-0) [2006\).](#page-10-0) Lesions to the prefrontal cortex produce symptoms characteristic of ADHD; distractibility, forgetfulness, impulsivity, poor planning, and locomotor hyperactivity [\(Arnsten, 2006\).](#page-10-0) Optimal levels of norepinephrine and dopamine have been shown to be required for efficient functioning of the prefrontal cortex [\(Arnsten, 2006\).](#page-10-0) Stimulant medication has been suggested to increase endogenous stimulation of α_{2A} -adrenoceptors and DRD1 receptors in the prefrontal cortex, optimizing prefrontal cortical regulation of behaviour and attention ([Arnsten,](#page-10-0) [2006\).](#page-10-0) Electrophysiological studies suggest that norepinephrine enhances "signals" by suppressing "noise" through postsynaptic α_{2A} -adrenoceptors in the prefrontal cortex while dopamine decreases "noise" through DRD1 activation [\(Arnsten, 2006\).](#page-10-0) Blockade of α_2 -adrenoceptors in the monkey prefrontal cortex produces the characteristic symptoms of ADHD, impaired working memory, increased impulsivity, and increased locomotor activity. Low doses of methylphenidate increased extracellular levels of both norepinephrine and dopamine in prefrontal cortex, strengthening prefrontal cortex regulatory output to parietal association areas, thereby inhibiting responses to irrelevant sensory stimuli and improving cognitive function [\(Arnsten and](#page-10-0) [Dudley, 2005\).](#page-10-0)

Although children with ADHD have smaller cerebellar volumes and psychostimulant drugs increase activity of the human cerebral vermis, no evidence has been found of a physiological role for dopamine in cerebellar function in non-human primates [\(Glaser et al., 2006\)](#page-11-0) arguing against the hypothesis that dopamine hypofunction is the primary disturbance in ADHD. The smaller cerebellar volume reflects a much greater problem in neural transmission and/or glial function.

3. Conclusion

ADHD is a heterogeneous disorder and so it is not surprising that different animal models mimic different aspects of ADHDlike behaviour. Diagnosis of ADHD is dependent on behavioural criteria. Animal models of the disorder must therefore not only mimic the fundamental behavioural characteristics of the disorder (face validity), they must also conform to a theoretical rationale for ADHD (construct validity) and predict aspects of ADHD behaviour, genetics, and neurobiology (predictive validity). SHR fulfill these validation criteria but other animal models have not been fully characterized in this respect. Primate models still need to develop their full potential and it has been suggested that selection based on poor performance of appropriate cognitive tasks could provide a model that is closest to the human disorder.

Nevertheless, the existing animal models of ADHD have provided unique insights into ADHD neurobiology. They emphasize the close interconnection between serotonergic, noradrenergic and dopaminergic systems. Changes in any one system can alter the function of the other monoaminergic systems and alter the underlying neural circuits that control behaviour. All of the animal models of ADHD result from disturbances of neural function (transient hyperthyroidism, deficient SNAP-25, impaired Ca^{2+} signaling, or disruption of the dopaminergic system) that occur during the early stages of development and give rise to compensatory changes in the monoaminergic systems.

There is convincing evidence to suggest that the activity of dopamine neurons is decreased in ADHD. Stimulus-evoked release of dopamine is decreased in several animal models including transgenic mice expressing mutant thyroid hormone receptor, the coloboma mutant mouse, 6-OHDA lesioned rat, DAT-KO mouse, poor performers in the 5-CSRT task and SHR. Evidence obtained from some animal models of ADHD suggest that the noradrenergic and serotonergic neurotransmitter systems may be the target of drugs that ameliorate ADHD symptoms.

One consequence of decreased stimulus-evoked release of dopamine would be decreased dopamine activation of DRD1 receptors on postsynaptic membranes and impaired rewardrelated learning of associations between predictive cues and behavioural consequences which could explain many of the symptoms of ADHD ([Sagvolden et al., 2005a,b\).](#page-13-0) Sustained attention is also controlled by noradrenergic projections from the locus coeruleus to association areas of the parietal and prefrontal cortex. There is considerable evidence to suggest that the noradrenergic system is poorly controlled by α_2 -autoreceptors in SHR, particularly at high norepinephrine release rates. This may be seen as hyperactivity of the noradrenergic system, especially when locus coeruleus neurons are stimulated in states of increased arousal. Impaired regulation of norepinephrine release in the prefrontal cortex could give rise to ADHD-like symptoms. More importantly, the balance between hypodopaminergic and hypernoradrenergic control of prefrontal cortex function appears to be a critical factor in determining ADHD symptomatology.

Acknowledgements

The author wishes to thank the University of Cape Town and South African Medical Research Council for support.

References

- American Academy of Pediatrics. Clinical practice guideline: diagnosis and evaluation of the child with attention-deficit/hyperactivity disorder. Pediatrics 2000;105:1158–70.
- Arnsten AFT. Catecholamine modulation of prefrontal cortical cognitive function. Trends Cogn Sci 1998;2:436–47.
- Arnsten AF. Fundamentals of attention-deficit/hyperactivity disorder: circuits and pathways. J Clin Psychiatr 2006;67(Suppl. 8):7–12.
- Arnsten AF, Dudley AG. Methylphenidate improves prefrontal cortical cognitive function through alpha2 adrenoceptor and dopamine D1 receptor actions: relevance to therapeutic effects in attention deficit hyperactivity disorder. Behav Brain Funct 2005;1:2.
- Aston-Jones G, Rajkowski J, Kubiak P, Alexinsky T. Locus coeruleus neurons in monkey are selectively activated by attended cues in a vigilance task. J Neurosci 1994;14:4467–80.
- Attwell D, Gibb A. Neuroenergetics and the kinetic design of excitatory synapses. Nat Rev Neurosci 2005;6:841–9.
- Barbelivien A, Ruotsalainen S, Sirviö J. Metabolic alterations in the prefrontal and cingulate cortices are related to behavioral deficits in a rodent model of attention-deficit hyperactivity disorder. Cereb Cortex 2001;11: 1056–63.
- Barr CL, Feng Y, Wigg K, Bloom S, Roberts W, Malone M, et al. Identification of DNA variants in the SNAP-25 gene and linkage study of these polymorphisms and attention-deficit hyperactivity disorder. Mol Psychiatr 2000;5:405–9.
- Barr AM, Lehmann-Masten V, Paulus M, Gainetdinov RR, Caron MG, Geyer MA. The selective serotonin-2A receptor antagonist M100907 reverses behavioral deficits in dopamine transporter knockout mice. Neuropsychopharmacology 2004;29:221–8.
- Berger DF, Sagvolden T. Sex differences in operant discrimination behaviour in an animal model of attention-deficit hyperactivity disorder. Behav Brain Res 1998;94:73–82.
- Berridge KC, Aldridge JW, Houchard KR, Zhuang X. Sequential superstereotypy of an instinctive fixed action pattern in hyper-dopaminergic mutant mice: a model of obsessive compulsive disorder and Tourette's. BMC Biol 2005;3:4.
- Biber K, Laurie DJ, Berthele A, Sommer B, Tolle TR, Gebicke-Harter PJ, et al. Expression and signaling of group I metabotropic glutamate receptors in astrocytes and microglia. J Neurochem 1999;72:1671–80.
- Biederman J, Faraone SV. Attention-deficit hyperactivity disorder. Lancet 2005;366:237–48.
- Biederman J, Spencer T, Wilens T. Evidence-based pharmacotherapy for attention-deficit hyperactivity disorder. Int J Neuropharmacol 2004;7:77–97.
- Bobb AJ, Castellanos FX, Addington AM, Rapoport JL. Molecular genetic studies of ADHD: 1991 to 2004. Am J Med Genet B: Neuropsychiatr Genet 2005;132:109–25.
- Bruno KJ, Freet CS, Twining RC, Egami K, Grigson PS, Hess EJ. Abnormal latent inhibition and impulsivity in coloboma mice, a model of ADHD. Neurobiol Dis; 2006.
- Bruno KJ, Hess EJ. The alpha(2C)-adrenergic receptor mediates hyperactivity of coloboma mice, a model of attention deficit hyperactivity disorder. Neurobiol Dis 2006;23:679–88.
- Bull E, Reavill C, Hagan JJ, Overend P, Jones DN. Evaluation of the spontaneously hypertensive rat as a model of attention deficit hyperactivity disorder: acquisition and performance of the DRL-60s test. Behav Brain Res 2000;109:27–35.
- Burd L, Klug MG, Coumbe MJ, Kerbeshian J. Children and adolescents with attention deficit-hyperactivity disorder. 1. Prevalence and cost of care. J Child Neurol 2003;18:555–61.
- Calzavara MB, Lopez GB, Abilio VC, Silva RH, Frussa-Filho R. Role of anxiety levels in memory performance of spontaneously hypertensive rats. Behav Pharmacol 2004;15:545–53.
- Carey MP, Diewald LM, Esposito F, Pellicano MP, Gironi Carnevale UA, Sergeant JA, et al. Differential distribution, affinity and plasticity of dopamine D-1 and D-2 receptors in the target sites of the mesolimbic system in an animal model of ADHD. Behav Brain Res 1998;94:173–85.
- Chan SH, Tai MH, Li CY, Chan JY. Reduction in molecular synthesis or enzyme activity of superoxide dismutases and catalase contributes to oxidative stress and neurogenic hypertension in spontaneously hypertensive rats. Free Radic Biol Med 2006;40:2028–39.
- Cheon KA, Ryu YH, Kim YK, Namkoong K, Kim CH, Lee JD. Dopamine transporter density in the basal ganglia assessed with [123I]IPT SPET in children with attention deficit hyperactivity disorder. Eur J Nucl Med 2003;30:306–11.
- Christiansen RE, Roald AB, Tenstad O, Iversen BM. Renal hemodynamics during development of hypertension in young spontaneously hypertensive rats. Kidney Blood Press Res 2002;25:322–8.
- Clements KM, Wainwright PE. Spontaneously hypertensive, Wistar–Kyoto and Sprague–Dawley rats differ in performance on a win-shift task in the water radial arm maze. Behav Brain Res 2006;167:295–304.
- Cook Jr EH, Stein MA, Krasowski MD, Cox NJ, Olkon DM, Kieffer JE, et al. Association of attention-deficit disorder and the dopamine transporter gene. Am J Hum Genet 1995;56:993–8.
- Davids E, Zhang K, Kula NS, Tarazi FI, Baldessarini RJ. Effects of norepinephrine and serotonin transporter inhibitors on hyperactivity induced by neonatal 6-hydroxydopamine lesioning in rats. J Pharmacol Exp Ther 2002;301:1097–102.
- Davids E, Zhang K, Tarazi FI, Baldessarini RJ. Animal models of attentiondeficit hyperactivity disorder. Brain Res Brain Res Rev 2003;42:1–21.
- Decamp E, Schneider JS. Attention and executive function deficits in chronic low-dose MPTP-treated non-human primates. Eur J Neurosci 2004;20:1371–8.
- Decamp E, Tinker JP, Schneider JS. Attentional cueing reverses deficits in spatial working memory task performance in chronic low dose MPTP-treated monkeys. Behav Brain Res 2004;152:259–62.
- De Jong W, Linthorst AC, Versteeg HG. The nigrostriatal dopamine system and the development of hypertension in the spontaneously hypertensive rat. Arch Mal Coeur Vaiss 1995;88:1193–6.
- Dell'Anna ME. Neonatal anoxia induces transitory hyperactivity, permanent spatial memory deficits and CA1 cell density reduction in developing rats. Behav Brain Res 1999;45:125–34.
- Dell'Anna ME, Luthman J, Lindqvist E, Olson L. Development of monoamine systems after neonatal anoxia in rats. Brain Res Bull 1993;32:159–70.
- de Villiers AS, Russell VA, Sagvolden T, Searson A, Jaffer A, Taljaard JJF. Alpha2-adrenoceptor mediated inhibition of [3H]dopamine release from nucleus accumbens slices and monoamine levels in a rat model for attention deficit hyperactivity disorder. Neurochem Res 1995;20:357–63.
- Doroshchuk AD, Postnov AI, Afanas'eva GV, Budnikov EI, Postnov I. Decreased ATP-synthesis ability of brain mitochondria in spontaneously hypertensive rats. Kardiologiia 2004;44:64–5.
- Dougherty DD, Bonab AA, Spencer TJ, Rauch SL, Madras BK, Fischman AJ. Dopamine transporter density in patients with attention deficit hyperactivity disorder. Lancet 1999;354:2132–3.
- Drouin C, Page M, Waterhouse B. Methylphenidate enhances noradrenergic transmission and suppresses mid- and long-latency sensory responses in the primary somatosensory cortex of awake rats. J Neurophysiol 2006;96: 622–32.
- Ernst M, Zametkin AJ, Matochik JA, Jons PH, Cohen RM. DOPA decarboxylase activity in attention deficit hyperactivity disorder adults. A [fluorine-18]fluorodopa positron emission tomographic study. J Neurosci 1998;18:5901–7.
- Ernst M, Zametkin AJ, Matochik JA, Pascualvaca D, Jons PH, Cohen RM. High midbrain [18F]DOPA accumulation in children with attention deficit hyperactivity disorder. Am J Psychiatr 1999;156:1209–15.
- Faraone SV. Genetics of adult attention-deficit/hyperactivity disorder. Psychiatr Clin N Am 2004;27:303–21.
- Faraone SV, Sergeant J, Gillberg C, Biederman J. The worldwide prevalence of ADHD: is it an American condition? World Psychiatr 2003;2:104–13.
- Fauaz G, Feres T, Farias NC, Paiva AC, Paiva TB. Characterization of alpha2 adrenoceptors in smooth muscles of the spontaneously hypertensive rat aorta. Vascul Pharmacol 2003;40:127–31.
- Fellner SK, Arendshorst WJ. Store-operated Ca2+ entry is exaggerated in fresh preglomerular vascular smooth muscle cells of SHR. Kidney Int 2002;61:2132–41.
- Ferguson SA, Cada AM. Spatial learning/memory and social and nonsocial behaviors in the spontaneously hypertensive, Wistar–Kyoto and Sprague–Dawley rat strains. Pharmacol Biochem Behav 2004;77:583–94.
- Franowicz JS, Kessler LE, Borja CM, Kobilka BK, Limbird LE, Arnsten AF. Mutation of the alpha2A-adrenoceptor impairs working memory performance and annuls cognitive enhancement by guanfacine. J Neurosci 2002;22:8771–7.
- Gainetdinov RR, Caron MG. An animal model of attention deficit hyperactivity disorder. Mol Med Today 2000;6:43–4.
- Gainetdinov RR, Caron MG. Genetics of childhood disorders. XXIV. ADHD, Part 8: hyperdopaminergic mice as an animal model of ADHD. J Am Acad Child Adolesc Psychiatr 2001;40:380–2.
- Gainetdinov RR, Jones SR, Caron MG. Functional hyperdopaminergia in dopamine transporter knock-out mice. Biol Psychiatr 1999;46:303–11.
- Gibson MA, Butters NS, Reynolds JN, Brien JF. Effects of chronic prenatal ethanol exposure on locomotor activity, and hippocampal weight, neurons, and nitric oxide synthase activity of the young postnatal guinea pig. Neurotoxicol Teratol 2000;22:183–92.
- Glaser PEA, Surgener SP, Grondin R, Gash CR, Palmer M, Castellanos FX, et al. Cerebellar neurotransmission in attention-deficit/hyperactivity disorder: does dopamine neurotransmission occur in the cerebellar vermis? J Neurosci Methods 2006;151:62–7.
- Glowinski J, Marin P, Tence M, Stella N, Giaume C, Premont J. Glial receptors and their intervention in astrocyto–astrocytic and astrocyto–neuronal interactions. Glia 1994;11:201–8.
- Granon S, Changeux JP. Attention-deficit/hyperactivity disorder: a plausible mouse model? Acta Paediatr 2006;95:645–9.
- Granon S, Passetti F, Thomas KL, Dalley JW, Everitt BJ, Robbins TW. Enhanced and impaired attentional performance after infusion of D1 dopaminergic receptor agents into rat prefrontal cortex. J Neurosci 2000;20:1208–15.
- Gross J, Muller I, Chen Y, Elizalde M, Leclere N, Herrera-Marschitz M, et al. Perinatal asphyxia induces region-specific long-term changes in mRNA levels of tyrosine hydroxylase and dopamine D(1) and D(2) receptors in rat brain. Brain Res Mol Brain Res 2000;79:110–7.
- Hand DJ, Fox AT, Reilly MP. Response acquisition with delayed reinforcement in a rodent model of attention-deficit/hyperactivity disorder (ADHD). Behav Brain Res 2006;175:337–42.
- Hausknecht KA, Acheson A, Farrar AM, Kieres AK, Shen RY, Richards JB, et al. Prenatal alcohol exposure causes attention deficits in male rats. Behav Neurosci 2005;119:302–10.
- Hernandez CM, Hoifodt H, Terry Jr AV. Spontaneously hypertensive rats: further evaluation of age-related memory performance and cholinergic marker expression. J Psychiatr Neurosci 2003;28:197–209.
- Hess EJ, Collins KA, Wilson MC. Mouse model of hyperkinesis implicates SNAP-25 in behavioral regulation. J Neurosci 1996;16:3104–11.
- Himelstein J, Newcorn JH, Halperin JM. The neurobiology of attention-deficit hyperactivity disorder. Front Biosci 2000;5:D461–78.
- Hironaka N, Ikeda K, Sora I, Uhl GR, Niki H. Food-reinforced operant behavior in dopamine transporter knockout mice: enhanced resistance to extinction. Ann NY Acad Sci 2004;1025:140–5.
- Horn JL, Janicki PK, Franks JJ. Diminished brain synaptic plasma membrane Ca(2+)-ATPase activity in spontaneously hypertensive rats: association with reduced anesthetic requirements. Life Sci 1995;56:L427–32.
- Iuvone L, Geloso MC, Dell'Anna E. Changes in open field behavior, spatial memory, and hippocampal parvalbumin immunoreactivity following enrichment in rats exposed to neonatal anoxia. Exp Neurol 1996;139:25–33.
- Jones SR, Gainetdinov RR, Jaber M, Giros B, Wightman RM, Caron MG. Profound neuronal plasticity in response to inactivation of the dopamine transporter. Proc Natl Acad Sci USA 1998;95:4029–34.
- Jones MD, Hess EJ. Norepinephrine regulates locomotor hyperactivity in the mouse mutant coloboma. Pharmacol Biochem Behav 2003;75:209–16.
- Jones MD, Williams ME, Hess EJ. Abnormal presynaptic catecholamine regulation in a hyperactive SNAP-25-deficient mouse mutant. Pharmacol Biochem Behav 2001a;68:669–76.
- Jones MD, Williams ME, Hess EJ. Expression of catecholaminergic mRNAs in the hyperactive mouse mutant coloboma. Brain Res Mol Brain Res 2001b;96:114–21.
- Jucaite A, Fernell E, Halldin C, Forssberg H, Farde L. Reduced midbrain dopamine transporter binding in male adolescents with attention-deficit/ hyperactivity disorder: association between striatal dopamine markers and motor hyperactivity. Biol Psychiatr 2005;57:229–38.
- Kirley A, Lowe N, Hawi Z, Mullins C, Daly G, Waldman I, et al. Association of the 480 bp DAT1 allele with methylphenidate response in a sample of Irish children with ADHD. Am J Med Genet B: Neuropsychiatr Genet 2003;121:50–4.
- Kirouac GJ, Ganguly PK. Up-regulation of dopamine receptors in the brain of the spontaneously hypertensive rat: an autoradiographic analysis. Neuroscience 1993;52:135–41.
- Knardahl S, Sagvolden T. Open-field behavior of spontaneously hypertensive rats. Behav Neural Biol 1979;27:187–200.
- Koskinen T, Ruotsalainen S, Puumala T, Lappalainen R, Koivisto E, Mannisto PT, et al. Activation of $5-HT_{2A}$ receptors impairs response control of

rats in a five-choice serial reaction time task. Neuropharmacology 2000;39: 471–81.

- Krause KH, Dresel SH, Krause J, Kung HF, Tatsch K. Increased striatal dopamine transporter in adult patients with attention deficit hyperactivity disorder: effects of methylphenidate as measured by single photon emission computed tomography. Neurosci Lett 2000;285:107–10.
- Lehohla M, Russell V, Kellaway L. NMDA-stimulated Ca2+ uptake into barrel cortex slices of spontaneously hypertensive rats. Metab Brain Dis 2001;16:133–41.
- Leo D, Sorrentino E, Volpicelli F, Eyman M, Greco D, Viggiano D, et al. Altered midbrain dopaminergic neurotransmission during development in an animal model of ADHD. Neurosci Biobehav Rev 2003;27:661–9.
- Levitan RD, Masellis M, Basile VS, Lam RW, Jain U, Kaplan AS, et al. Polymorphism of the serotonin-2A receptor gene (HTR2A) associated with childhood attention deficit hyperactivity disorder (ADHD) in adult women with seasonal affective disorder. J Affect Disord 2002;71:229–33.
- Linthorst AC, de Lang H, De Jong W, Versteeg DH. Effect of the dopamine D2 receptor agonist quinpirole on the in vivo release of dopamine in the caudate nucleus of hypertensive rats. Eur J Pharmacol 1991;201:125–33.
- Linthorst AC, Van den Buuse M, De Jong W, Versteeg DH. Electrically stimulated [3H]dopamine and [14C]acetylcholine release from nucleus caudatus slices: differences between spontaneously hypertensive rats and Wistar–Kyoto rats. Brain Res 1990;509:266–72.
- Linthorst AC, van Giersbergen PL, Gras M, Versteeg DH, De Jong W. The nigrostriatal dopamine system: role in the development of hypertension in spontaneously hypertensive rats. Brain Res 1994;639:261–8.
- Lou HC. Etiology and pathogenesis of attention-deficit hyperactivity disorder (ADHD): significance of prematurity and perinatal hypoxic–haemodynamic encephalopathy. Acta Paediatr 1996;85:1266–71.
- Luthman J, Fredriksson A, Lewander T, Jonsson G, Archer T. Effects of *d*amphetamine and methylphentdate on hyperactivity produced by neonatal 6-hydroxydopamine treatment. Psychopharmacology (Berl) 1989;99:550–7.
- Marcil J, Thibault C, Anand-Srivastava MB. Enhanced expression of G_i-protein precedes the development of blood pressure in spontaneously hypertensive rats. J Mol Cell Cardiol 1997;29:1009–22.
- Mick E, Biederman J, Faraone SV, Sayer J, Kleinman S. Case–control study of attention-deficit hyperactivity disorder and maternal smoking, alcohol use, and drug use during pregnancy. J Am Acad Child Adolesc Psychiatr 2002;41:378–85.
- Milberger S, Biederman J, Faraone SV, Jones J. Further evidence of an association between maternal smoking during pregnancy and attention deficit hyperactivity disorder: findings from a high-risk sample of siblings. J Clin Child Psychol 1998;27:352–8.
- Mill J, Curran S, Kent L, Gould A, Huckett L, Richards S, et al. Association study of a SNAP-25 microsatellite and attention deficit hyperactivity disorder. Am J Med Genet 2002;114:269–71.
- Mill J, Sagvolden T, Asherson P. Sequence analysis of DRD2, DRD4, and DAT1 in SHR and WKY rat strains. Behav Brain Funct 2005;1:24.
- Mook DM, Jeffrey J, Neuringer A. Spontaneously hypertensive rats (SHR) readily learn to vary but not repeat instrumental responses. Behav Neural Biol 1993;59:126–35.
- Myers MM, Whittemore SR, Hendley ED. Changes in catecholamine neuronal uptake and receptor binding in the brains of spontaneously hypertensive rats (SHR). Brain Res 1981;220:325–38.
- Nakamura-Palacios EM, Caldas CK, Fiorini A, Chagas KD, Chagas KN, Vasquez EC. Deficits of spatial learning and working memory in spontaneously hypertensive rats. Behav Brain Res 1996;74:217–27.
- Nash K, Rovet J, Greenbaum R, Fantus E, Nulman I, Koren G. Identifying the behavioural phenotype in Fetal Alcohol Spectrum Disorder: sensitivity, specificity and screening potential. Arch Womens Ment Health 2006;9:181–6.
- Ohno Y, Matsuo K, Suzuki H, Tanase H, Serikawa T, Takano T, et al. Genetic linkage of the sarco(endo)plasmic reticulum Ca(2+)-dependent ATPase II gene to intracellular Ca2+ concentration in the spontaneously hypertensive rat. Biochem Biophys Res Commun 1996;227:789–93.
- Ohno Y, Matsuo K, Suzuki H, Tanase H, Takano T, Saruta T. Increased intracellular Ca2+ is not coinherited with an inferred major gene locus for hypertension (ht) in the spontaneously hypertensive rat. Am J Hypertens 1997;10:282–8.
- Ohno Y, Suzuki H, Tanase H, Otsuka K, Sasaki T, Suzawa T, et al. Quantitative trait loci mapping for intracellular calcium in spontaneously hypertensive rats. Am J Hypertens 2005;18:666–71.
- Okamoto K, Aoki K. Development of a strain of spontaneously hypertensive rats. Jpn Circ J 1963;27:282–93.
- Oshima T, Young EW, McCarron DA. Abnormal platelet and lymphocyte calcium handling in prehypertensive rats. Hypertension 1991;18:111–5.
- Papa M, Sagvolden T, Sergeant JA, Sadile AG. Reduced CaMKII-positive neurones in the accumbens shell of an animal model of attention-deficit hyperactivity disorder. Neuroreport 1996;7:3017–20.
- Papa M, Sergeant JA, Sadile AG. Differential expression of transcription factors in the accumbens of an animal model of ADHD. Neuroreport 1997;8:1607–12.
- Paz R, Barsness B, Martenson T, Tanner D, Allan AM. Behavioral teratogenicity induced by nonforced maternal nicotine consumption. Neuropsychopharmacology; 2006.
- Prediger RD, Pamplona FA, Fernandes D, Takahashi RN. Caffeine improves spatial learning deficits in an animal model of attention deficit hyperactivity disorder (ADHD)—the spontaneously hypertensive rat (SHR). Int J Neuropsychopharmacol 2005;8:583–94.
- Printz MP, Jirout M, Jaworski R, Alemayehu A, Kren V. Genetic models in applied physiology. HXB/BXH rat recombinant inbred strain platform: a newly enhanced tool for cardiovascular, behavioral, and developmental genetics and genomics. J Appl Physiol 2003;94:2510–22.
- Puumala T, Ruotsalainen S, Jakala P, Koivisto E, Riekkinen Jr P, Sirvio J. ¨ Behavioral and pharmacological studies on the validation of a new animal model for attention deficit hyperactivity disorder. Neurobiol Learn Mem 1996;66:198–211.
- Quist JF, Barr CL, Schachar R, Roberts W, Malone M, Tannock R, et al. Evidence for the serotonin HTR2A receptor gene as a susceptibility factor in attention deficit hyperactivity disorder (ADHD). Mol Psychiatr 2000;5:537–41.
- Raber J, Mehta PP, Kreifeldt M, Parsons LH, Weiss F, Bloom FE, et al. Coloboma hyperactive mutant mice exhibit regional and transmitter-specific deficits in neurotransmission. J Neurochem 1997;68:176–86.
- Rastogi RB, Singhal RL. Influence of neonatal and adult hyperthyroidism on behavior and biosynthetic capacity for norepinephrine, dopamine and 5 hydroxytryptamine in rat brain. J Pharmacol Exp Ther 1976;198:609–18.
- Realmuto GM, Garfinkel BD, Tuchman M, Tsai MY, Chang PN, Fisch RO, et al. Psychiatric diagnosis and behavioral characteristics of phenylketonuric children. J Nerv Ment Dis 1986;174:536–40.
- Reja V, Goodchild AK, Phillips JK, Pilowsky PM. Tyrosine hydroxylase gene expression in ventrolateral medulla oblongata of WKY and SHR: a quantitative real-time polymerase chain reaction study. Auton Neurosci 2002a;98:79–84.
- Reja V, Goodchild AK, Pilowsky PM. Catecholamine-related gene expression correlates with blood pressures in SHR. Hypertension 2002b;40:342–7.
- Riikonen RS, Nokelainen P, Valkonen K, Kolehmainen AI, Kumpulainen KI, Kononen M, et al. Deep serotonergic and dopaminergic structures in fetal alcoholic syndrome: a study with nor-beta-CIT-single-photon emission computed tomography and magnetic resonance imaging volumetry. Biol Psychiatr 2005;57:1565–72.
- Robbins TW. The 5-choice serial reaction time task: behavioural pharmacology and functional neurochemistry. Psychopharmacology (Berl) 2002; 163:362–80.
- Roeltgen DP, Schneider JS. Chronic low-dose MPTP in nonhuman primates: a possible model for attention deficit disorder. J Child Neurol 1991;6(Suppl.):S82–9.
- Roeltgen DP, Schneider JS. Task persistence and learning ability in normal and chronic low dose MPTP-treated monkeys. Behav Brain Res 1994;60:115–24.
- Romano E, Tremblay RE, Farhat A, Cote S. Development and prediction of hyperactive symptoms from 2 to 7 years in a population-based sample. Pediatrics 2006;117:2101–10.
- Russell VA. Increased AMPA receptor function in slices containing the prefrontal cortex of spontaneously hypertensive rats. Metab Brain Dis 2001;16:143–9.
- Russell VA. Hypodopaminergic and hypernoradrenergic activity in prefrontal cortex slices of an animal model for attention-deficit hyperactivity disorder the spontaneously hypertensive rat. Behav Brain Res 2002;130:191–6.
- Russell V, Allie S, Wiggins T. Increased noradrenergic activity in prefrontal cortex slices of an animal model for attention-deficit hyperactivity disorder—the spontaneously hypertensive rat. Behav Brain Res 2000a;117:69–74.
- Russell VA, de Villiers A, Sagvolden T, Lamm M, Taljaard J. Altered dopaminergic function in the prefrontal cortex, nucleus accumbens and caudate-putamen of an animal model of attention-deficit hyperactivity disorder—the spontaneously hypertensive rat. Brain Res 1995;676:343–51.
- Russell VA, de Villiers A, Sagvolden T, Lamm M, Taljaard J. Differences between electrically-, ritalin- and D-amphetamine-stimulated release of [³H]dopamine from brain slices suggest impaired vesicular storage of dopamine in an animal model of attention-deficit hyperactivity disorder. Behav Brain Res 1998;94:163–71.
- Russell VA, de Villiers AS, Sagvolden T, Lamm MCL, Taljaard JJF. Methylphenidate affects striatal dopamine differently in an animal model for attention-deficit hyperactivity disorder—the spontaneously hypertensive rat. Brain Res Bull 2000b;53:187–93.
- Russell VA, Oades RD, Tannock R, Killeen PR, Auerbach JG, Johansen EB, et al. Response variability in attention-deficit hyperactivity disorder: a neuronal and glial energetics hypothesis. Behav Brain Funct 2006;2:30.
- Russell VA, Sagvolden T, Johansen EB. Animal models of attention-deficit hyperactivity disorder. Behav Brain Funct 2005;1:9.
- Russell VA, Wiggins TM. Increased glutamate-stimulated norepinephrine release from prefrontal cortex slices of spontaneously hypertensive rats. Metab Brain Dis 2000;15:297–304.
- Sagvolden T. Behavioral validation of the spontaneously hypertensive rat (SHR) as an animal model of attention-deficit/hyperactivity disorder (AD/HD). Neurosci Biobehav Rev 2000;24:31–9.
- Sagvolden T, Hendley ED, Knardahl S. Behavior of hypertensive and hyperactive rat strains: hyperactivity is not unitarily determined. Physiol Behav 1992a;52:49–57.
- Sagvolden T, Johansen EB, Aase H, Russell VA. A dynamic developmental theory of attention-deficit/hyperactivity disorder (ADHD) predominantly hyperactive/impulsive and combined subtypes. Behav Brain Sci 2005a;28:397–419.
- Sagvolden T, Metzger MA, Schiørbeck HK, Rugland AL, Spinnangr I, Sagvolden G. The spontaneously hypertensive rat (SHR) as an animal model of childhood hyperactivity (ADHD): changed reactivity to reinforcers and to psychomotor stimulants. Behav Neural Biol 1992b;58:103–12.
- Sagvolden T, Pettersen MB, Larsen MC. Spontaneously hypertensive rats (SHR) as a putative animal model of childhood hyperkinesis: SHR behavior compared to four other rat strains. Physiol Behav 1993;54:1047–55.
- Sagvolden T, Russell VA, Aase H, Johansen EB, Farshbaf M. Rodent models of attention-deficit/hyperactivity disorder. Biol Psychiatr 2005b;57: 1239–47.
- Schneider JS, Sun ZQ, Roeltgen DP. Effects of dopamine agonists on delayed response performance in chronic low-dose MPTP-treated monkeys. Pharmacol Biochem Behav 1994;48:235–40.
- Shaywitz BA, Klopper JH, Gordon JW. Methylphenidate in 6-hydroxydopamine-treated developing rat pups: effects on activity and maze performance. Arch Neurol 1978;35:463–9.
- Shen RY, Choong KC. Different adaptations in ventral tegmental area dopamine neurons in control and ethanol exposed rats after methylphenidate treatment. Biol Psychiatr 2006;59:635–42.
- Siesser WB, Zhao J, Miller LR, Cheng SY, McDonald MP. Transgenic mice expressing a human mutant beta1 thyroid receptor are hyperactive, impulsive, and inattentive. Genes Brain Behav 2006;5:282–97.
- Solanto MV. Neuropsychopharmacological mechanisms of stimulant drug action in attention-deficit hyperactivity disorder: a review and integration. Behav Brain Res 1998;94:127–52.
- Sullivan JE, Chang P. Review: emotional and behavioral functioning in phenylketonuria. J Pediatr Psychol 1999;24:281–99.
- Tabet F, Savoia C, Schiffrin EL, Touyz RM. Differential calcium regulation by hydrogen peroxide and superoxide in vascular smooth muscle cells from spontaneously hypertensive rats. J Cardiovasc Pharmacol 2004;44: 200–8.
- Thapar A, Fowler T, Rice F, Scourfield J, van den BM, Thomas H, et al. Maternal smoking during pregnancy and attention deficit hyperactivity disorder symptoms in offspring. Am J Psychiatr 2003;160:1985–9.
- Thapar A, O'Donovan M, Owen MJ. The genetics of attention deficit hyperactivity disorder. Hum Mol Genet 2005;14(Spec. No. 2):R275–82.
- Toga AW, Thompson PM, Sowell ER. Mapping brain maturation. Trends Neurosci 2006;29:148–59.
- Trinh JV, Nehrenberg DL, Jacobsen JP, Caron MG, Wetsel WC. Differential psychostimulant-induced activation of neural circuits in dopamine transporter knockout and wild type mice. Neuroscience 2003;118:297–310.
- Tsuda K, Tsuda S, Masuyama Y, Goldstein M. Norepinephrine release and neuropeptide Y in medulla oblongata of spontaneously hypertensive rats. Hypertension 1990;15:784–90.
- Tsuda K, Tsuda S, Nishio I. Role of protein kinase C in the regulation of acetylcholine release in the central nervous system of spontaneously hypertensive rats. J Cardiovasc Pharmacol 2003;41(Suppl. 1):S57–60.
- Ueno K, Togashi H, Matsumoto M, Ohashi S, Saito H, Yoshioka M. Alpha4beta2 nicotinic acetylcholine receptor activation ameliorates impairment of spontaneous alternation behavior in stroke-prone spontaneously hypertensive rats, an animal model of attention deficit hyperactivity disorder. J Pharmacol Exp Ther 2002a;302:95–100.
- Ueno KI, Togashi H, Mori K, Matsumoto M, Ohashi S, Hoshino A, et al. Behavioural and pharmacological relevance of stroke-prone spontaneously hypertensive rats as an animal model of a developmental disorder. Behav Pharmacol 2002b;13:1–13.
- van den Bergh FS, Bloemarts E, Chan JS, Groenink L, Olivier B, Oosting RS. Spontaneously hypertensive rats do not predict symptoms of attention-deficit hyperactivity disorder. Pharmacol Biochem Behav 2006;83:380–90.
- Van den Buuse M. Prepulse inhibition of acoustic startle in spontaneously hypertensive rats. Behav Brain Res 2004;154:331–7.
- Vendruscolo LF, Terenina-Rigaldie E, Raba F, Ramos A, Takahashi RN, Mormede P. A QTL on rat chromosome 7 modulates prepulse inhibition, a neuro-behavioral trait of ADHD, in a Lewis × SHR intercross. Behav Brain Funct 2006;2:21.
- Watanabe Y, Fujita M, Ito Y, Okada T, Kusuoka H, Nishimura T. Brain dopamine transporter in spontaneously hypertensive rats. J Nucl Med 1997;38:470–4.
- Wiersema JR, van der Meere JJ, Roeyers H. ERP correlates of impaired error monitoring in children with ADHD. J Neural Transm; 2005.
- Wilson MC. Coloboma mouse mutant as an animal model of hyperkinesis and attention deficit hyperactivity disorder. Neurosci Biobehav Rev 2000;24:51–7.
- Wultz B, Sagvolden T. The hyperactive spontaneously hypertensive rat learns to sit still, but not to stop bursts of responses with short interresponse times. Behav Genet 1992;22:415–33.
- Wyss JM, Fisk G, Van Groen T. Impaired learning and memory in mature spontaneously hypertensive rats. Brain Res 1992;592:135–40.
- Xu C, Shen RY. Amphetamine normalizes the electrical activity of dopamine neurons in the ventral tegmental area following prenatal ethanol exposure. J Pharmacol Exp Ther 2001;297:746–52.
- Yang PB, Amini B, Swann AC, Dafny N. Strain differences in the behavioral responses of male rats to chronically administered methylphenidate. Brain Res 2003;971:139–52.
- Zhang K, Davids E, Tarazi FI, Baldessarini RJ. Effects of dopamine D4 receptor-selective antagonists on motor hyperactivity in rats with neonatal 6-hydroxydopamine lesions. Psychopharmacology (Berl) 2002a;161:100–6.
- Zhang K, Davids E, Tarazi FI, Baldessarini RJ. Serotonin transporter binding increases in caudate-putamen and nucleus accumbens after neonatal 6-hydroxydopamine lesions in rats: implications for motor hyperactivity. Brain Res Dev Brain Res 2002b;137:135–8.
- Zhang K, Tarazi FI, Baldessarini RJ. Role of dopamine D(4) receptors in motor hyperactivity induced by neonatal 6-hydroxydopamine lesions in rats. Neuropsychopharmacology 2001;25:624–32.
- Zhuang X, Oosting RS, Jones SR, Gainetdinov RR, Miller GW, Caron MG, et al. Hyperactivity and impaired response habituation in hyperdopaminergic mice. Proc Natl Acad Sci USA 2001;98:1982–7.